These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 17434015)

  • 1. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation.
    Dinger JC; Heinemann LA; Kühl-Habich D
    Contraception; 2007 May; 75(5):344-54. PubMed ID: 17434015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives.
    Dinger J; Bardenheuer K; Heinemann K
    Contraception; 2014 Apr; 89(4):253-63. PubMed ID: 24576793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives.
    Dinger J; Möhner S; Heinemann K
    Contraception; 2016 May; 93(5):378-85. PubMed ID: 26825258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives.
    Loughlin J; Seeger JD; Eng PM; Foegh M; Clifford CR; Cutone J; Walker AM
    Contraception; 2008 Nov; 78(5):377-83. PubMed ID: 18929734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives.
    Seeger JD; Loughlin J; Eng PM; Clifford CR; Cutone J; Walker AM
    Obstet Gynecol; 2007 Sep; 110(3):587-93. PubMed ID: 17766604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes.
    Mona Eng P; Seeger JD; Loughlin J; Oh K; Walker AM
    Contraception; 2007 Feb; 75(2):101-7. PubMed ID: 17241838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products.
    Sehovic N; Smith KP
    Ann Pharmacother; 2010 May; 44(5):898-903. PubMed ID: 20371756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The truth about oral contraceptives and venous thromboembolism.
    Shulman LP; Goldzieher JW
    J Reprod Med; 2003 Nov; 48(11 Suppl):930-8. PubMed ID: 14686030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experiences with drospirenone: from reproductive to postmenopausal years.
    Pérez-López FR
    Maturitas; 2008 Jun; 60(2):78-91. PubMed ID: 18468818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of a new oral contraceptive containing drospirenone.
    Heinemann LA; Dinger J
    Drug Saf; 2004; 27(13):1001-18. PubMed ID: 15471507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms.
    Sangthawan M; Taneepanichskul S
    Contraception; 2005 Jan; 71(1):1-7. PubMed ID: 15639064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol.
    Kluft C; Endrikat J; Mulder SM; Gerlinger C; Heithecker R
    Contraception; 2006 Apr; 73(4):336-43. PubMed ID: 16531162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of a large-scale surveillance system in Planned Parenthood Federation of America clinics to monitor cardiovascular events in users of combination oral contraceptives.
    Burnhill MS
    Int J Fertil Womens Med; 1999; 44(1):19-30. PubMed ID: 10206196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yasmin: the reason why.
    Thorneycroft IH
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data.
    Jick SS; Hernandez RK
    BMJ; 2011 Apr; 342():d2151. PubMed ID: 21511805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of deep venous thrombosis with oral contraceptives containing drospirenone.
    Dunn N
    BMJ; 2011 Apr; 342():d2519. PubMed ID: 21511807
    [No Abstract]   [Full Text] [Related]  

  • 18. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of estrogen type on cardiovascular safety of combined oral contraceptives.
    Dinger J; Do Minh T; Heinemann K
    Contraception; 2016 Oct; 94(4):328-39. PubMed ID: 27343748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC Study).
    Dinger JC; Bardenheuer K; Assmann A
    BMC Med Res Methodol; 2009 Nov; 9():77. PubMed ID: 19922634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.